Long-term follow-up of hepatitis B virus carriers with normal transaminases levels.

Turk J Pediatr

Department of Pediatrics, Hacettepe University, Faculty of Medicine, Ankara.

Published: October 1998

There has been very little data recorded on the natural course of chronic hepatitis B virus infection in asymptomatic children. In order to assess the natural course of liver disease in hepatitis B surface antigen (HBsAg) carriers with normal liver tests, 124 such children (81 males, 65.3%) were followed for six to 144 months (mean 36.8 +/- 22.8 months). Liver tests and hepatitis B virus (HBV) markers were tested at least every six months. In the beginning, hepatitis B e antigen (HBeAg) was positive in 61 (53%) of the 115 carriers of HBsAg who were tested. Anti-HBe was positive in 51 (44.3%), and both HBeAg antigen and anti-HBe were negative in three (2.7%) carriers. The prevalence of HBeAg was not affected by the patient's age or sex. During follow-up, 11 patients (18%) lost HBeAg (a mean annual clearance rate of 5.8%), and 12 patients (9.7%) lost HBsAg (a mean annual clearance rate of 3.1%). We found no difference in the clearance of HBsAg and HBeAg by age and sex. The presence of another HBsAg positive person in the family affected HBsAg clearance rate but not HBeAg clearance. Only seven patients (5 HBeAg positive and 2 anti-HBe positive) developed transient elevations in liver transaminases. Three of five HBeAg positive children cleared HBeAg after transaminases elevations. Of the five patients who underwent percutaneous liver biopsies, non-specific changes were found. It is concluded that hepatitis B carriers with normal liver tests should be followed with liver function tests alone and that long-term prognosis is good.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hepatitis virus
12
carriers normal
12
liver tests
12
hbeag positive
12
clearance rate
12
hbeag
9
natural course
8
normal liver
8
anti-hbe positive
8
age sex
8

Similar Publications

Hepatitis C virus (HCV) presents a significant global health issue due to its widespread prevalence and the absence of a reliable vaccine for prevention. While significant progress has been achieved in therapeutic interventions since the disease was first identified, its resurgence underscores the need for innovative strategies to combat it. The nonstructural protein NS5A is crucial in the life cycle of the HCV, serving as a significant factor in both viral replication and assembly processes.

View Article and Find Full Text PDF

Background: Conflicting results have been reported on the impact of tenofovir versus entecavir on liver-related outcomes.

Aims: To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)-infected patients and compare the impact of tenofovir versus entecavir on the risk of hepatocellular carcinoma (HCC), liver transplantation (LT) and mortality.

Methods: We used the French National Health Insurance Databases (SNDS) to identify HBV-infected patients.

View Article and Find Full Text PDF

Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are known as the most common blood-borne viral infections worldwide. Individuals referring to drop-in centers (DICs) are considered high-risk people exposed to infection with blood-borne viruses. The purpose of this study was to investigate the prevalence of HIV, HBV, and HCV infections among women referred to DICs in Lorestan Province, western Iran.

View Article and Find Full Text PDF

Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults.

BMC Med

December 2024

Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, 100191, China.

Background: Risk prediction models can identify individuals at high risk of chronic liver disease (CLD), but there is limited evidence on the performance of various models in diverse populations. We aimed to systematically review CLD prediction models, meta-analyze their performance, and externally validate them in 0.5 million Chinese adults in the China Kadoorie Biobank (CKB).

View Article and Find Full Text PDF

The natural history of chronic hepatitis C virus (HCV) infection has changed after the introduction of direct-acting antiviral agents (DAAs). Screening programs have been ongoing to reach the World Health Organisation's goal of HCV elimination by 2030, and most infected people are eligible for treatment. Given the increased cardiovascular risk in people with HCV infection and the metabolic pathways of DAAs, it is not uncommon to face the issue of drug-drug interactions (DDIs) with antiplatelet or anticoagulant drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!